Statins reduce intratumor cholesterol affecting adrenocortical cancer growth
Francesca Trotta1*, Paola Avena1*, Adele Chimento1*, Vittoria Rago1, Arianna De Luca1, Sara Sculco1, Marta C. Nocito1, Rocco Malivindi1, Francesco Fallo2, Raffaele Pezzani2, Catia Pilon2, Francesco M. Lasorsa3, Simona N. Barile3, Luigi Palmieri3, Antonio M. Lerario4, Vincenzo Pezzi1 ** , Ivan Casaburi1#, Rosa Sirianni1 **
1Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Cosenza, Italy.
2Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 105, 35128 Padua, Italy.
3Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, and CNR Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies Bari, Italy
4Departments of Molecular & Integrative Physiology and Internal Medicine, University of Michigan, Medical School, Ann Arbor, MI, USA.
Dept. of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), 87036 Italy.
Vincenzo Pezzi, PhD Dept. of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS),
Short title: Statins reduce ACC growth
HMGCR: 3-Hydroxy-3-Methylglutaryl-CoA Reductase
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 *Contributed equally #Co-senior authors 18 19 ** Co-corresponding Rosa Sirianni, PhD 20 21 22 23 24 Phone: +39 0984 493182 25 Fax: +39 0984 493157 26 27 28 29 30 87036 Italy. 31 Phone: +39 0984 493148 32 Fax: +39 0984 493157 33 34 35 36 Abbreviations 37 ACC: adrenocortical cancer; 38 39 ERa: estrogen receptor alpha,
Author Manuscript Published OnlineFirst on June 16, 2020; DOI: 10.1158/1535-7163.MCT-19-1063 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
40
COXIV: cytochrome c oxidase OCR: oxygen consumption rate
41
42
43
The authors declare no potential conflicts of interest.
44 Abstract
Mitotane causes hypercholesterolemia in ACC patients. We suppose that cholesterol increases within the tumor and can be used to activate proliferative pathways. In this study, we used statins to decrease intratumor cholesterol and investigated the effects on ACC growth related to ERa action at the nuclear and mitochondrial levels. We first used microarray to investigate mitotane effect on genes involved in cholesterol homeostasis and evaluated their relationship with patients’ survival in ACC TCGA. We then blocked cholesterol synthesis with simvastatin and determined the effects on H295R cell proliferation, estradiol production and ERa activity in vitro and in xenograft tumors. We found that mitotane increases intratumor cholesterol content and expression of genes involved in cholesterol homeostasis, among them INSIG, whose expression affects patients’ survival. Treatment of H295R cells with simvastatin to block cholesterol synthesis decreased cellular cholesterol content and this affected cell viability. Simvastatin reduced estradiol production and decreased nuclear and mitochondrial ERa function. A mitochondrial target of ERa, the respiratory complex IV (COX IV) was reduced after simvastatin treatment, which profoundly affected mitochondrial respiration activating apoptosis. In vivo experiments confirmed the ability of simvastatin to reduce tumor volume and weight of grafted H295R cells, intratumor cholesterol content, Ki- 67 and ERa, COX IV expression and activity and increase TUNEL positive cells. Collectively these data demonstrate that a reduction in intratumor cholesterol content prevents estradiol production, inhibits mitochondrial respiratory chain inducing apoptosis in ACC cells. Inhibition of mitochondrial respiration by simvastatin represents a novel strategy to counteract ACC growth.
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
Introduction
Adrenocortical carcinoma (ACC) is a rare but aggressive cancer with a very poor prognosis. At present the only valuable option for ACC therapy is an early prognosis followed by surgical resection of the tumor. Mitotane (1,1-dichloro-2-(ochlorophenyl)-2-(p-chloro-phenyl)-ethane or o,p- DDD), an inhibitor of steroid synthesis with adrenolytic activity, alone or combined with cytotoxic drugs such as etoposide, doxorubicin, and platinum agents, is the only specific treatment for ACC (1). Overall survival rate at 5-years is 16-38%, but in the case of metastatic disease (stage IV), survival rate at 5 years drops to less than 10 % (2). Because mitotane treatment has a relatively low response rate and carries significant systemic toxicity, better treatment methods are critically needed for more effective targeting and inhibition of ACC.
Mitotane works by inhibiting cytochrome P450s involved in steroid synthesis and by inhibiting SOAT1, an enzyme involved in cholesterol esterification, leading to an increase in free cholesterol toxic to the cell. Mitotane serum concentrations above 14 mg/l are required for its therapeutic effects (3). However, even with administration of high doses, effective mitotane serum concentrations are achieved in only half of patients and are never reached in others (4). Doses below 14 mg/l are less effective in inhibiting SOAT1, but still able to induce 3-hydroxy-3- methylglutaryl-coenzyme A reductase (HMGCR) activity in the liver (5), favoring an increase in serum cholesterol levels, a side effect that ACC patients experience during mitotane treatment (6). Possibly, the increase in serum cholesterol will allow the adrenal tumor to have a higher uptake. Alternatively, a direct effect of mitotane on adrenal HMGCR, impacting de novo synthesis, cannot be excluded, since the adrenal can synthesize cholesterol in the endoplasmic reticulum (7). Both uptake or de novo synthesis will increase cholesterol availability within the tumor cells, favoring activation of proliferative mechanisms.
Our previous studies have demonstrated that ACC is characterized by aromatase over-expression (8) and insulin-like growth factor II (IGF-II) (resulting overexpressed in 90% of ACCs and activating an autocrine mitogenic effect) can induce aromatase transcription (9). Then, it is possible that in ACC patients, despite normal circulating estrogen levels, a higher local estrogen production can occur, allowing estrogens, through estrogen receptor a (ERa), to foster ACC progression.
A study performed on 152 ACC patients showed that increased intra-abdominal fat is associated with tumor worsening and decreased survival (10). The rise in fat deposition observed in mitotane- treated patients can also be responsible for increased estradiol production, since the adipose tissue has high aromatase expression, which can convert steroid precursors into estrogens (11). Importantly, it has been recently suggested that adipose tissue may contain the steroidogenic machinery necessary for the initiation of de novo steroid biosynthesis from cholesterol (12). The
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98
increase in cholesterol and body fat is also responsible for lowering hematic mitotane concentration, since the drug is a lipophilic compound and accumulates into circulating lipoprotein fractions and high-lipid-containing tissues (13).
A drug capable of reducing cholesterol synthesis both at hepatic and intratumor level would be effective in preventing ACC growth. In this study we propose statins, drugs that target HMGCR, largely used to reduce hypercholesterolemia, as a valid treatment for ACC. By reducing cholesterol synthesis within the tumor cells, statins could be a reliable mean to prevent estrogen production and then action through ERa in ACC.
99 100 101 102 103 104 105 106
Materials and Methods
Detailed experimental information is provided in the Supplemental Experimental Procedures.
Cell cultures and tissue
H295R, SW13 and Y1 cells were purchased from ATCC. H295R were cultured as previously described (14). SW13 were maintained in DMEM/F-12 with 10% fetal bovine serum (FBS). Y1 cells were maintained in DMEM/F-12 with 2.5% FBS and 15% horse serum. Cell monolayers were subcultured into 6 well plates for protein and RNA extraction (4 x 106 cells/plate) and 12 multi-well for colony formation assay (1x 103 cells/well) and grown for 14 days. Cells were treated with statins or mitotane (Sigma) in DMEM/F-12 containing 10% FBS.
Fresh-frozen samples of adrenocortical tumors, removed at surgery, were collected at the hospital- based Divisions of the University of Padua (Italy). Tissue samples were obtained with the approval of local ethics committees and written informed consent from patients. Studies were conducted in accordance with the Declaration of Helsinki guidelines as revised in 1983 and approved by the institutional review board of the University of Padua. Diagnosis of malignancy was performed according to the histopathological criteria proposed by Weiss et al. (15) and the modification proposed by Aubert et al. (16). Patients included in the mitotane-treated group received the drug for at least 4 months at the dose of 4-6 g/day.
MTT assay
The effect of simvastatin on cell viability was measured using 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazoliumbromide (MTT) assay as previously described (17). Briefly, cells were cultured in complete medium in 48 well plates (1×104 cells/well) for 48 h, then treated in 10% FBS medium for 24, 48 or 72 h. Fresh MTT (Sigma), resuspended in PBS, was then added to each well (final concentration 0.33 mg/mL). After 2h incubation, cells were lysed with 200 ul of DMSO and optical density was measured at 570 nm in a multi plate reader (Synergy H1, BioTek, Agilent).
Intracellular cholesterol extraction and colorimetric cholesterol assay
Cholesterol was measured using a colorimetric cholesterol assay kit (Cell Biolabs). Intracellular cholesterol was extracted from cells using a mixture of chloroform, isopropanol and NP-40 (7: 11: 0.1). The same mix was added to tumor samples of known weight, and lysed using stainless steel beads in the Bullet Blender Tissue Homogenizer (Next Advance, Inc .; Troy, NY USA). Purified water was then added to lysed samples, and upon centrifugation, the organic, bottom phase was taken and dried by vacuum centrifugation. The resulting lipid pellet was resuspended in 200 ul of
107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 139 140 141 142 143 144 145 146 147 148 149 150 151 152
1X cholesterol assay buffer. Then, 50 uL of sample were processed according to manufacturer’s instruction.
ELISA for Estradiol
The H295R cells were kept in complete medium for 48h in multi-wells of 12 (1x105 cells/well) and treated in DMEM F-12 enriched with 5% DCC-FBS (FBS treated with Dextran coated in order to repair steroids) with increasing doses of simvastatin (2.5-5-10 µM). After 48 hours of treatment the contents of 17ß-estradiol (E2) was measured by means of ELISA (enzyme-linked immuno- absorbent assay) (NovaTec) following manufacturer’s instruction.
Spheroids culture
A single cell suspension was prepared using enzymatic (1X Trypsin-EDTA, Sigma Aldrich, #T3924), and manual disaggregation (25 gauge needle) (18). Cells were plated at a density of 500 cells/cm2 in spheroids medium (DMEM-F12/B27/EGF (20ng/ml)/ Pen-Strep) in non-adherent conditions, in culture dishes coated with (2-hydroxyethylmethacrylate) (poly-HEMA, Sigma, #P3932). Cells were grown for 5 days and maintained in a humidified incubator at 37°℃ at an atmospheric pressure in 5% (v/v) carbon dioxide/air. After 5 days of culture, spheres >50 um were counted using an eye piece graticule, and the percentage of cells plated which formed spheres was calculated and is referred to as percentage spheroids formation, and was normalized to one (1 = 100% TSFE, tumor-spheres formation efficiency). Cells were directly seeded on low-attachment plates in the presence of treatments.
Colony formation
The NCI-H295R cells were plated in 12-well plates (1x103) and allowed to attach. Treatment commenced for 24 hours with drug alone. Untreated or simvastatin-treated cells were controls. The medium was changed and surviving cells were allowed to grow colonies of ≥50 cells for 2 weeks, washed, fixed, and stained with Coomassie blue, and counted. Total colony numbers were normalized to untreated controls.
Protein extraction and Western-blotting
H295R cells were cultured in complete medium for 48 hours in 100 mm plates (2x106 cells) before being treated in complete medium with simvastatin for 48 hours and then used for cytosolic and mitochondrial protein extraction. The extracts were then analyzed by western blotting (WB).
153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185
Total proteins were prepared using RIPA buffer. Equal amounts of proteins were subjected to WB analysis. Blots were incubated overnight at 4 ℃ with primary antibodies. Membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Amersham) and immunoreactive bands were visualized with the ECL (Amersham).
Xenograft experiments
All animal procedures approved by the Ethics Research Committee University animals from Calabria (protocol No. 1077/2016-PR from the Ministry of Health to Dr. Sirianni) were performed in female Foxn1nu mice (Harlen Envigo) mice. Following H295R xenograft establishment, mice received 4 mg/kg/d of simvastatin in the water for 24 days, and tumors were harvested and weighed. The water with the treatment has been replaced every week. The dose was chosen to equal the therapeutic dose used for patients of 20 mg/d (based on the equivalence of body surface area) (19).
Immunohistochemistry
IHC experiments were performed using 8 mm thick paraffin-embedded sections of H295R xenograft tumors from mice treated with vehicle or simvastatin. Slides were deparaffinized and dehydrated and incubated over-night at 4℃ with Aromatase (MBL International Corporation, Woburn, MA, USA, MCA2077S, 1:50), COXIV (Abcam, ab14744, 1:200), Ki-67 (DAKO, M7240, 1:100), CCNE (Bethyl, IHC-00341, 1:100), ERa (Santa Cruz, sc-8002, 1:50), TOM20 (Santa Cruz, sc-17764, 1:100) primary antibodies. Then, a horse biotinylated anti-mouse/rabbit IgG was applied for 1h at RT, to form the avidin biotin horseradish peroxidase complex (Vector Laboratories). Immunoreactivity was visualized by DAB (Vector Laboratories). For ERa detection was used a FITC-conjugated secondary antibodies (Santa Cruz) for 1h at RT. Fluorescent images were collected on Olympus fluorescent microscope.
Oil red O staining
H295R cells (1x106) were plated on glass coverslips for 48h and then treated for 48h with simvastatin (10 µM). The cells were washed with cold phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 30 min at RT. Then, the cells were stained with 0.5% Oil Red O (Sigma-Aldrich, St. Louis, MO, USA) solution for 20 min at RT and counterstained with hematoxylin for 2 min, followed by PBS washes and microscopic evaluation.
Cytochrome C oxidase (COX)/complex IV activity
186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218
Cryostat sections (8 um) were prepared and stored at -80℃ until use. For the COX activity staining, frozen sections were brought to RT, washed for 5 min with 25 mM sodium phosphate buffer, pH 7.4, and then incubated for 0.5, 1 or 2 h at 37℃ with the COX incubation mixture. The COX solution consisted of 10 mg Cytochrome C (cat# C7752, Sigma-Aldrich), 10 mg 3,3’- diaminobenzidine tetrahydrochloride hydrate (cat# D5637, Sigma-Aldrich) and 2 mg catalase (cat# C1345, Sigma-Aldrich) dissolved in 10 ml of 25 mM sodium phosphate buffer. The solution was filtered after preparation and the pH was adjusted to 7.2-7.4 with 1 N NaOH.
HMGCR activity assay
The HMGCR activity in H295R lysates was measured with HMGCR Activity Assay Kit (CS1090, Sigma, USA) according to manufacturer’s instructions. The assay is based on the spectrophotometric measurement of the decrease in absorbance at 340 nm, which represents the oxidation of NADPH by the catalytic subunit of HMGCR in the presence of the substrate HMG- CoA. Cells were lysed in RIPA buffer containing protease inhibitors. Two microliters of cell lysate were used to measure HMGCR activity. One unit converts 1.0 umol of NADPH to NADP+ per 1 min at 37°C. The unit specific activity is defined as umol/min/mg protein (units/mg P).
Detection of apoptosis by TUNEL assay
The induction of apoptosis was assessed by the TUNEL assay (Terminal deoxynucleotidyl transferase dUTP Nick End Labeling), a method that evaluates the fragmentation of DNA. The click-it® TUNEL Alexa Fluor® Imaging Assay kit (Invitrogen) was used, following the manufacturer’s instructions. Sections of vehicle- and simvastatin-treated tumors from paraffin- embedded H295R xenografts were cut to a thickness of 5 um, deparaffinized and dehydrated and then used for the assay.
Seahorse XFe96 metabolic flux analysis
Real-time oxygen consumption rates (OCR) for H295R cells treated with simvastatin or vehicle (control) were determined using the Seahorse Extracellular Flux (XF96) analyzer (Seahorse Bioscience, MA, USA). H295R cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM GlutaMAX, and 1% Pen/Strep. 7x104 cells were seeded per well into XF96-well cell culture plates (Seahorse Bioscience, MA, USA), and incubated overnight at 37℃ in a 5% CO2 humidified atmosphere. After 24h, cells were treated with simvastatin (2.5, 5 and 10 µM) for 48h. At the end of treatment, cells were processed as previously published (20).
219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252
Microarray
H295R cells (1x105) were plated on 60 mm dishes for 48h and then treated for 24h with Mitotane (25 µM). RNA was extracted using PureLinkTM RNA Mini Kit (Thermo Fisher). The quality of total RNA was first assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA). Biotin-labeled cDNA targets were synthesized starting from 150 ng of total RNA. Double stranded cDNA synthesis and related cRNA was performed with GeneChip® WT Plus Kit (Affymetrix, Santa Clara, CA). With the same kit was synthesized the sense strand cDNA before to be fragmented and labeled. All steps of the labeling protocol were performed as suggested by Affymetrix, starting from 5.5 ug of ssDNA. Hybridization was performed using the GeneChip® Hybridization, Wash and Stain Kit. A single GeneChip® Clariom S was then hybridized with each biotin-labeled sense target. GeneChip arrays were scanned using an Affymetrix GeneChip® Scanner 3000 7G using default parameters. Affymetrix GeneChip® Command Console software (AGCC) was used to acquire GeneChip® images and generate .DAT and CEL files, which were used for subsequent analysis with proprietary software.
RNA extraction, reverse transcription and real time PCR
Following total RNA extraction, 1 ug of total RNA was reverse transcribed and then used for PCR reactions were performed in the iCycler iQ Detection System (Bio-Rad Laboratories S.r.l., Milano, Italia). Final results were expressed as n-fold differences in gene expression relative to 18S and calibrator, calculated using the 44Ct method as previously shown (14).
Patients’ data analysis
Gene expression and survival data were obtained using two independent cohorts of adrenocortical tumors were used: Expression Cohort included 33 ACC, 22 ACA (adrenocortical adenoma) and 10 NA (normal adrenal) (GEO dataset GSE33371) and TCGA cohort included 78 ACC (https://portal.gdc.cancer.gov/legacy-archive).
Statistics
All experiments were performed at least three times. Data were expressed as mean values + standard error), statistical significance between control and treated samples was analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc .; La Jolla, CA) software. Control and treated groups were compared using t-test or the analysis of variance (ANOVA). Significance was defined as p < 0.05. Microarray data analysis was performed using Partek Genomics Suite software (PGS), version 6.6 (6.16.0812 for Mac). Affymetrix CEL-files were extracted, normalized and summarized using
253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286
RMA algorithm (CEL file imported by Partek on Wed Feb 21 10:25:17 2018; Probes to Import: Interrogating Probes; Probe filtering: skip; Algorithm: RMA; Background Correction: RMA Background Correction; Normalization: Quantile Normalization; Log Probes using Base: 2; Probeset Summarization: Median Polish) (21-23). Genes differentially expressed were identified using a t-test.
287 288 289 290 291
Results
Mitotane increases intratumor cholesterol content by affecting expression of genes involved in the regulation of cholesterol homeostasis.
Here we wanted to determine if mitotane can also increase cholesterol content in the tumor. As it can be seen in Fig. 1A, cholesterol is increased in ACC from patients treated with mitotane compared to tumors from ACC patients that underwent surgery prior to any treatment. A key enzyme in cholesterol synthesis is HMGCoA reductase (HMGCR). We conducted a retrospective analysis of publicly available microarray data from ACC patients’ cohorts. Expression levels of HMGCR are higher in ACC when compared to the normal adrenal (NC) (Fig. 1B). However, its expression does not affect patients’ survival (Fig. 1C). We evaluated HMGCR protein expression and activity in H295R cells after 2 and 14 days of mitotane treatment. As previously demonstrated in hepatocytes, mitotane increases the enzyme activity (Fig. 1D).
We also used H295R cells treated with mitotane for 24 hours to perform gene expression microarray analysis. Using as cutoff of 1.5 in fold change and a p value ≤ 0.05 we identified 344 transcripts regulated by mitotane. Importantly, an enrichment analysis for the categories of Gene Ontology (GO), indicated that the drug preferentially increases expression of genes involved in metabolism, and more specifically we looked into cholesterol metabolism (Fig. 1E). Among the genes present in this GO group we further investigated sterol regulatory element-binding protein 1 (SREBP1) and Insulin induced gene 1 (INSIG1) encoding for proteins working as cholesterol sensors, and ATP-binding cassette sub-family G member 1 (ABCG1), encoding for a protein that mediates cholesterol efflux from the cells to ApoA1 (apolipoprotein A1), a component of HDL. Results from microarray were confirmed by real-time PCR using short-term (24h) and long-term (2 weeks and 3 weeks) mitotane-treated H295R cells. As observed in microarray data, SREBP1, INSIG1, and ABCG1 expression was decreased after 24h treatment (Fig. 1F, 1I, 1L). On the long term treatment, expression of SREBP1 was maintained low (Fig. 1G). Survival data for this factor show that when its expression is low patients have a trend to a worse outcome, even if not significant (Fig. 1H). For INSIG1 and ABCG1 we found that long term treatment with mitotane did not produce a decrease in gene expression, but mRNA levels were kept similar to those seen in untreated samples (Fig. 1J, 1M). The higher expression of these genes maintained in the presence of increased cholesterol amounts (caused by mitotane) indicate loss of cell ability to sense cholesterol levels. Importantly, survival data for INSIG indicate that higher expression is associated with worse survival (Fig. 1K). A similar trend in the association was observed for ABCG1, even if there was not a significant difference between the two groups (Fig. 1N).
317 318 319 320 321 322 323 324 325
292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316
A decrease in ACC intracellular cholesterol positively associates with decreased tumor growth in vitro and in vivo.
The use of simvastatin was able to reduce H295R cell viability in a time and dose-dependent manner (Fig. 2A). Importantly, the decreased cell viability was rescued by addition of mevalonate, the product of HMGCoA reductase activity (Fig. 2B). These effects were reproduced by fluvastatin and rosuvastatin, (Fig. S1A). Additionally, we used two additional cell lines, SW13 and Y1, and found that all tested statins produced effects similar two those observed in H295R cells (Fig. S1 B, C). In the clonogenic assay, simvastatin treated cells formed significantly less colonies when compared to vehicle treated cells, illustrating the tumor suppressor function of this drug (Fig. 2C). When H295R cells were grown as spheroids in the presence of simvastatin, we observed a substantial dose-dependent decrease in sphere numbers (Fig. 2D). To evaluate if intratumor cholesterol depletion could reduce ACC growth in vivo, xenografts were generated by implanting H295R cells in the flank of athymic nude mice. When tumors reached an average of 200 mm3 mice were administered vehicle versus simvastatin at 4 mg/kg/day for 24 days and tumors were measured twice a week. Tumor growth of the statin treated group was significantly smaller than the vehicle treated group (Fig. 2E). Tumor volume at the end of the experiment was 60% smaller in animals receiving simvastatin (Fig. 2E), and tumor weight was decreased by 58% (Fig. 2F). In parallel with the decline in tumor size with simvastatin, there was a decrease in Ki-67 staining (Fig. 2G and Fig. S2A).
Decreased cholesterol availability in ACC impairs estradiol production
After 48h treatment simvastatin at the dose of 10 uM caused a 33% reduction in intracellular cholesterol (Fig. 3A). We also evaluated cholesterol content in of H295R xenografts. By adjusting to tissue weight we found a concentration of 9 ng/mg of tissue, while statin decreased this amount to 6.3 ng/mg of tissue (Fig. 3B). In addition, frozen sections from tumors were stained for lipids using Oil Red O, less red stain is observed in treated tumors, indicative of a reduced amount of lipid deposition (Fig. 3B and Fig. S2B). Thus, intratumor cholesterol has an important cell-autonomous role in ACC growth and in parallel statins lessens ACC tumor development. Treatment of H295R cells for 48h with increasing concentrations of simvastatin decreased E2 production in a dose dependent manner, as demonstrated by ELISA of H295R culture media, with 10 uM producing a 50% decrease in E2 content (Fig. 3C). When we evaluated aromatase (CYP19) gene expression we did not find any change in mRNA, neither in vitro (Fig. 3D) nor in vivo (Fig. 3G), indicating that simvastatin does not affect transcriptional regulation of this gene. In fact, expression of steroidogenic factor 1 (SF-1) did not change after simvastatin treatment (Fig. 3E). However, WB
326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359
analysis indicated a decrease in aromatase protein content following statin treatment of H295R (Fig. 3F), data that was confirmed by IHC on xenografts tumors (Fig. 3H and Fig. S2C). Additionally, the presence of mevalonate was able to overcome the inhibition on aromatase expression seen in the presence of simvastatin (Fig. S3A).
Decreased E2 availability in ACC impairs ERa function.
ERa has a role in regulating transcription of mitochondrial genes involved in cellular respiration (24). We evaluated both nuclear and mitochondrial ERa activity after simvastatin treatment. Expression of ERa was decreased by simvastatin in vitro (Fig. 4A Fig. S4A and S4B) and in vivo (Fig. 4B Fig. S2D), a similar effect was observed on cyclin E, a known target of ERa, both in vitro and in vivo (Fig. 4C, D Fig. S2E). Additionally, the presence of mevalonate was able to overcome the inhibition on ERa expression seen in the presence of simvastatin (Fig. S3A).
These effects are opposite to those elicited by E2, which instead increased cyclin E expression (Fig. S3B). Mitochondrial protein fraction was used for WB analysis of ERa, we observed that simvastatin treated samples had a lower content of the nuclear receptor (Fig. 4E). WB analysis of all the components of the respiratory chain (COX I to IV plus ATP synthase) can be performed using a mix of 5 different antibodies (OX-PHOS). With this approach we identified a decreased expression of COXIV (Fig. 4F and S4A, S4B), a known target of ERa. On the contrary, E2 treatment increased COXIV expression, and is able to prevent statin inhibitory effect (Fig. S3C). Data were also confirmed on statin-treated xenografts where we observed a reduced COXIV expression (Fig. 4G and Fig. S2F) and activity (Fig. 4H and Fig. S2G) compared to vehicle treated xenografts. We monitored cellular oxygen consumption rates (OCR), and demonstrated that simvastatin is able to reduce oxygen consumption in a dose-dependent manner (Fig. 5A). Statin exposure profoundly affected the oxidative metabolism of H295R cells. Indeed, 16 h of treatment induced a clear dose-dependent decrease of the basal (Fig. 5B) and maximal respiration (Fig. 5C) as well as ATP turnover (Fig. 5E) and spare capacity (Fig. 5F). No effect was observed on proton leak (Fig. 5D). We also used immunoblotting to monitor the abundance of a known reliable marker of mitochondrial mass, TOM20, in response to simvastatin treatment. We found that treated H295R cells displayed a reduced expression of TOM20, in vitro and in vivo (Fig. 5G, 5H and Fig. S2H).
Decreased cholesterol availability in ACC activates an apoptotic pathway.
BAK expression and PARP-1 cleavage, were increased in H295R cells treated for 48h with simvastatin, indicating activation of apoptosis (Fig. 6A and Fig. S4C, S4D), further confirmed by TUNEL assay (Fig. 6B). Similarly, evaluation of apoptosis on H295R xenografts sections revealed
360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393
an increase of TUNEL positive cells under simvastatin treatment (Fig. 6C). Since Bak gene is under c-Jun transcriptional control (25), we evaluated c-Jun protein levels after simvastatin treatment. After 48h we observed increased levels of c-Jun and its phosphorylation status, as well as increased levels of pERK1/2, whose sustained activation is associated with apoptosis (26). Addition of mevalonate prevented activation of these kinases in response to simvastatin (Fig. 6D and Fig. S4C, S4D). Specific inhibitors for ERK1/2 and JNK abrogated Jun and ERK1/2 activation/phosphorylation preventing apoptosis, as indicated by the loss of PARP1 cleavage. These data indicate ERK1/2 and JNK as part of simvastatin-induced apoptotic mechanism (Fig. 6E). Similarly to simvastatin, fluvastatin and rosuvastatin inhibited estrogen signaling and activated apoptosis in H295R cells (Fig. S4E and S4F).
394 395 396 397 398 399 400 401 402 403
Discussion
Mitotane represents the first-line therapy for patients with ACC. However, mitotane alone or combined with chemotherapy shows limited efficacy on advanced disease. In addition, mitotane has high toxicity and several side effects among which hypercholesterolemia (6,27). Data from almost 40 years ago report the ability of mitotane to increase liver HMGCR activity in vitro and in vivo (5). Since the adrenal synthesizes cholesterol de novo, mitotane could have a direct effect on adrenal cholesterol synthesis. Having higher cholesterol bioavailability, tumor cells can foster their own growth. To support our hypothesis, we first demonstrate an increase in intratumor cholesterol in ACC patients treated with mitotane compared to untreated patients. Using previously published microarray data publically available (28) we demonstrated the presence of increased HMGCR expression in ACC samples, which, however, was not associated with decreased survival rate. Increased intratumor cholesterol following mitotane treatment could be due to an increased activity of HMGCR rather than to an increased expression, with the former influencing survival more than the latter. Microarray analysis of mitotane-treated H295R cells helped us in identifying genes involved in cholesterol metabolism and modulated by the drug. Among them, we validated INSIG1, SREBP1 and ABCG1. INSIG1 encodes for a protein that retains a chaperone protein (SCAP) in the endoplasmic reticulum, SCAP is necessary for delivery of SREBP1 to the Golgi, where SREBP1 becomes active. SREBP1, increases transcription of cholesterol synthesizing genes among which HMGCR (29).
Short-term mitotane decreases INSIG1 and SREBP1 expression, while long term-mitotane maintains low SREBP1 but high INSIG1 expression. When looking at survival data of ACC patients, high INSIG1 is associated with a shorter survival. ABCG1 belongs to the family of ATP binding cassette and mediates cholesterol efflux (30). Its expression is decreased by short-term mitotane treatment, but this effect is lost after prolonged treatment, favoring cholesterol accumulation. Since, mitotane has a prevalent accumulation in adipose tissue, the circulating levels are often reduced (13,31), and the therapeutic concentrations of mitotane (between 14-20 µg/mL, 40-60uM) are not always reached in patients. Importantly, lower doses (10 and 25 uM) produce effects that are different from what seen using 40uM. This raises a question, could cells, in the presence of lower doses of mitotane, escape the normal control of cholesterol homeostasis? Can the increase in cholesterol be responsible for long-term adjustment to mitotane?
Several reports propose a promising role for statins in cancer treatment (32). Here we demonstrate that simvastatin can reduce intratumor cholesterol synthesis. Based on MTT assay IC50 for simvastatin was calculated to be 10 uM. Since 1 µM simvastatin in the media corresponds to the dose of 0.4586 mg/kg of body weight, we decided to treat mice with 4 mg/Kg/day. This dose is
404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437
equivalent to a human dose of 20 mg/d based on body surface area equivalency. This dose was effective in producing more that 60% decrease in tumor growth. Importantly, this dose decreased intratumor cholesterol content, supporting our hypothesis that a reduction in intratumor cholesterol can decrease ACC growth. Interest for statins is not new for the therapy of ACC, however, it has been considered in association with mitotane to reduce hypercholesterolemia (6,33). Our data instead suggest the possibility of using lipophilic statins without mitotane but eventually with cytotoxic drugs. Simvastatin, which appears to be the most effective among the tested drugs, shouldn’t be combined with mitotane, which is a known inducer of CYP3A4, a member of the cytochrome P450 family involved in simvastatin metabolism. A recent case-study evaluated management of hypercholesterolemia induced by mitotane treatment. A patient was co- administered with mitotane and statins, but despite cholesterol lowering drugs, it was observed a rise for total cholesterol and LDL-c level. Importantly the patient had 2 local recurrences within a 7 year-period, however, the course of ACC in this patient’s case has been better than average. This data supports our hypothesis that cholesterol can be implicated in ACC progression.
Cholesterol in tumor adrenal cells is used for steroid synthesis, and a decrease in its availability would affect estradiol production. Our previous study demonstrated that E2 increases tumor growth, and Tamoxifen, which blocks ERa activity, prevents its effects (9). With this information as background, we wanted to investigate if the reduced E2 production, seen after simvastatin treatment, could interfere with ERa function. We first observed a reduction in CCNE, a known nuclear target of ERa. Additionally, we investigated if the expression of mitochondrial targets of ERa could be influenced by simvastatin. To support a role for ERa in the mitochondria of tumor adrenal, we show that E2 treatment increases the amount of COXIV levels and prevents simvastatin inhibitory effect.
466 467 468 469 470 471
Additionally, it was reported a direct effect of statins on mitochondrial function, consequent to a deficiency of complex I (34). The novelty of our data is the involvement of ERa/complex IV in statin-mediated apoptosis. The reduction in COXIV alters the functioning of mitochondrial respiration, changing the mitochondrial potential ultimately leading to organelle damage. High COXIV activity within the tumor occurs in a significant subset of patients with high grade gliomas and is an independent predictor of poor outcome (35). Importantly, it has been postulated that COXIV activity may be required for the anchorage-independent growth of lung cancer cells (36). In general, mitochondria appear to be an appealing target for the treatment of cancer (37). Effects on COXIV negatively influence mitochondrial function as demonstrated by reduced oxygen consumption rate (OCR). We have previously demonstrated that a reduced cell growth is observed in breast cancer cells treated with XCT790, a drug that targets ERRa, a master regulator of cell
438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465
metabolism. ERRa inhibition reduces OCR and prevents tumor growth (20). We have also used XCT790 to block ERRa in ACC and demonstrated its efficacy in reducing tumor growth (38), further establishing that impairing mitochondrial function, reduces ACC growth. It has been shown that mitotane significantly impairs mitochondrial respiratory chain function by selectively inhibiting enzymatic complex IV activity. However, as a consequence of respiratory chain inhibition, mitotane causes a compensatory increase of mitochondrial biogenesis (39). Differently from mitotane, simvastatin reduces TOM20, a marker of mitochondrial mass. Reduced mitochondrial function after treatment with simvastatin causes cell death by apoptosis, the same type of cell death that is observed in H295R and SW13 cells in response to mitotane. This apoptotic mechanism requires activation of c-Jun and sustained ERK1/2 phosphorylation. Farnesyl pyrophosphate (FPP) or geranylgeranyl pyrophosphate (GGPP) are products of mevalonate that can be anchored onto intracellular proteins through prenylation, thereby ensuring the re-localization of the target proteins in the cell membranes (40-42). Ras is a prenylated protein upstream of ERK1/2 activation. The observation that ERK1/2 phosphorylation is maintained in the presence of simvastatin, evidences that its phosphorylation is independent of Ras and potentially involves different pathways. We found that ERK phosphorylation is prevented by addition of p38 and JNK inhibitors, implicating these kinases in the observed sustained ERK activation. Jun expression and activation are increased by treatment with simvastatin and are reversed by addition of mevalonate, which also prevents PARP-1 cleavage, confirming that the apoptotic mechanism is dependent on cholesterol depletion.
Collectively our data support the hypothesis of using statins for the treatment of ACC. Further preclinical studies are warranted to establish effects on tumor growth when used in combination with chemotherapy. However, their use in therapy as cholesterol lowering drugs will easily translate preclinical studies into a clinical trial.
472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494
Authors’ Contributions
Conception and design: Ivan Casaburi, Vincenzo Pezzi, Rosa Sirianni
Development of methodology: Francesca Trotta, Adele Chimento, Paola Avena, Vittoria Rago, Arianna De Luca, Francesco M. Lasorsa, Simona N. Basile, Sara Sculco, Marta Nocito, Rosa Sirianni, Ivan Casaburi,
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Rocco Malivindi, Francesca Trotta, Rosa Sirianni,
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Antonio M. Lerario, Francesco M. Lasorsa, Simona N. Basile, Luigi Palmieri, Raffaele Pezzani, Francesco Fallo, Catia Pilon, Rosa Sirianni, Ivan Casaburi,
Writing, review, and/or revision of the manuscript: Rosa Sirianni, Ivan Casaburi, Adele Chimento, Paola Avena
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Francesca Trotta, Arianna De Luca,
Study supervision: Ivan Casaburi, Vincenzo Pezzi, Rosa Sirianni
Acknowledgments
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), grant IG15230 to Dr Rosa Sirianni and IG20122 to Dr Vincenzo Pezzi; Drs Trotta Francesca and Paola Avena were supported by a fellowship from AIRC.
495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514
References
1. Kirschner LS. The next generation of therapies for adrenocortical cancers. Trends in endocrinology and metabolism: TEM 2012;23(7):343-50 doi 10.1016/j.tem.2012.04.001.
2. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009;115(2):243-50 doi 10.1002/cncr.24030.
3. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, et al. Plasma concentrations of o,p’DDD, o,p’DDA, and o,p’DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. The Journal of clinical endocrinology and metabolism 2011;96(6):1844-51 doi 10.1210/jc.2010-2676.
4. Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism 2013;98(12):4759-67 doi 10.1210/jc.2013-2281.
5. Stacpoole PW, Varnado CE, Island DP. Stimulation of rat liver 3-hydroxy-3-methylglutaryl- coenzyme A reductase activity by o,p’-DDD. Biochemical pharmacology 1982;31(5):857- 60.
6. Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p’DDD-induced hypercholesterolaemia. The Quarterly journal of medicine 1992;84(305):671-9.
7. Miller WL. Steroidogenesis: Unanswered Questions. Trends in endocrinology and metabolism: TEM 2017;28(11):771-93 doi 10.1016/j.tem.2017.09.002.
8. Barzon L, Masi G, Pacenti M, Trevisan M, Fallo F, Remo A, et al. Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Archiv : an international journal of pathology 2008;452(2):181-91 doi 10.1007/s00428-007-0542-0.
9. Sirianni R, Zolea F, Chimento A, Ruggiero C, Cerquetti L, Fallo F, et al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. The Journal of clinical endocrinology and metabolism 2012;97(12):E2238-50 doi 10.1210/jc.2012-2374.
10. Miller BS, Ignatoski KM, Daignault S, Lindland C, Doherty M, Gauger PG, et al. Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World journal of surgery 2012;36(7):1509-16 doi 10.1007/s00268-012-1581-5.
11. Simpson ER. Sources of estrogen and their importance. The Journal of steroid biochemistry and molecular biology 2003;86(3-5):225-30.
12. Li J, Papadopoulos V, Vihma V. Steroid biosynthesis in adipose tissue. Steroids 2015;103:89-104 doi 10.1016/j.steroids.2015.03.016.
515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554
13. Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, et al. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism 2015;100(8):2890-8 doi 10.1210/JC.2015-2080.
14. Chimento A, Sirianni R, Casaburi I, Zolea F, Rizza P, Avena P, et al. GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget 2015;6(22):19190-203 doi 10.18632/oncotarget.4241.
15. Weiss LM, Medeiros LJ, Vickery AL, Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. The American journal of surgical pathology 1989;13(3):202-6.
16. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. The American journal of surgical pathology 2002;26(12):1612-9.
17. De Luca A, Avena P, Sirianni R, Chimento A, Fallo F, Pilon C, et al. Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth. Cells 2017;6(4) doi 10.3390/cells6040042.
18. Shaw FL, Harrison H, Spence K, Ablett MP, Simões BM, Farnie G, et al. A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity. Journal of Mammary Gland Biology and Neoplasia 2012;17(2):111-7 doi 10.1007/s10911-012- 9255-3.
19. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2008;22(3):659-61 doi 10.1096/fj.07-9574LSF.
20. De Luca A, Fiorillo M, Peiris-Pages M, Ozsvari B, Smith DL, Sanchez-Alvarez R, et al. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. Oncotarget 2015;6(17):14777-95 doi 10.18632/oncotarget.4401.
21. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19(2):185-93 doi 10.1093/bioinformatics/19.2.185.
22. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic acids research 2003;31(4):e15 doi 10.1093/nar/gng015.
23. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 2004;99(468):909-17 doi 10.1198/016214504000000683.
24. Chen JQ, Cammarata PR, Baines CP, Yager JD. Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochimica et biophysica acta 2009;1793(10):1540-70 doi 10.1016/j.bbamcr.2009.06.001.
555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592
25. Jin HO, Park IC, An S, Lee HC, Woo SH, Hong YJ, et al. Up-regulation of Bak and Bim via JNK downstream pathway in the response to nitric oxide in human glioblastoma cells. Journal of cellular physiology 2006;206(2):477-86 doi 10.1002/jcp.20488.
26. Cagnol S, Chambard JC. ERK and cell death: mechanisms of ERK-induced cell death — apoptosis, autophagy and senescence. The FEBS journal 2010;277(1):2-21 doi 10.1111/j.1742-4658.2009.07366.x.
27. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-related cancer 2008;15(4):1043-53 doi 10.1677/ERC-08-0103.
28. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. The Journal of clinical endocrinology and metabolism 2009;94(1):204-12 doi 10.1210/jc.2008- 1456.
29. Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World journal of gastroenterology 2004;10(21):3081-7.
30. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arteriosclerosis, thrombosis, and vascular biology 2010;30(2):139-43 doi 10.1161/ATVBAHA.108.179283.
31. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring. European journal of cancer & clinical oncology 1984;20(1):47-53.
32. Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J. Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer treatment reviews 2015;41(6):554-67 doi 10.1016/j.ctrv.2015.04.005.
33. Tsakiridou ED, Liberopoulos E, Giotaki Z, Tigas S. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer. Journal of clinical lipidology 2018; 12(3):826-9 doi 10.1016/j.jacl.2018.03.078.
34. Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochemical and biophysical research communications 2005;338(3):1426-34 doi 10.1016/j.bbrc.2005.10.108.
35. Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, et al. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PloS one 2013;8(4):e61035 doi 10.1371/journal.pone.0061035.
36. Telang S, Nelson KK, Siow DL, Yalcin A, Thornburg JM, Imbert-Fernandez Y, et al. Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Molecular cancer 2012;11:60 doi 10.1186/1476-4598-11-60.
37. Ralph SJ, Neuzil J. Mitochondria as targets for cancer therapy. Molecular nutrition & food research 2009;53(1):9-28 doi 10.1002/mnfr.200800044.
593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631
38. Casaburi I, Avena P, De Luca A, Chimento A, Sirianni R, Malivindi R, et al. Estrogen related receptor alpha (ERRalpha) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget 2015;6(28):25135-48 doi 10.18632/oncotarget.4722.
39. Hescot S, Slama A, Lombes A, Paci A, Remy H, Leboulleux S, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-related cancer 2013;20(3):371-81 doi 10.1530/ERC-12- 0368.
40. Nishida S, Matsuoka H, Tsubaki M, Tanimori Y, Yanae M, Fujii Y, et al. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. Molecular and cellular biochemistry 2005;269(1-2):109-14.
41. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et al. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. Journal of experimental & clinical cancer research : CR 2011;30:74 doi 10.1186/1756-9966-30-74.
42. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer research 2004;64(18):6461-8 doi 10.1158/0008-5472.CAN-04-0866.
632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648
Figure legends
FIGURE 1. Mitotane changes the expression of genes involved in cholesterol homeostasis in ACC and negatively affects patients’ survival. A) Cholesterol was extracted from human ACC samples and its content (ng/mg tissue) measured by colorimetric assay (- Mitotane, n=5, + Mitotane, n=7, *p<0.03). B) Box plot graph for HMGCR gene expression in ACA (adrenocortical adenoma), ACC (adrenocortical carcinoma) and NC (normal adrenal) human samples. ACC-ACA: p-value=0.08, ACA-NC: p-value=0.26, ACC-NC: p-value=0.26. Statistical significance was calculated using limma. C) Survival time in ACC patients according to HMGCR gene expression. D) HMGCR expression and activity was evaluated in H295R cells untreated (basal) or treated for 2 and 14 days with mitotane 10uM. E) RNA from H295R cells left untreated (basal) or treated for 24h with mitotane (25uM) was processed for microarray analysis. Enrichment analysis for the categories GO and heat map from microarray data with the most highly up-regulated (red) and down-regulated (blue) genes involved in the cholesterol biosynthesis pathway. F-G, I-J, L-M) mRNA expression of SREBP1 (F-G), INSIG1 (I-J) and ABCG1 (L-M) in H295R cells. The mRNA was extracted and analyzed by QPCR from cells left untreated (0) or treated for 24 h with Mitotane (10-25-40 µM) (F-I-L) and from cells untreated (0) or treated for different weeks (2 or 3 weeks, w) with Mitotane (10uM) (G-J-M). Each sample was normalized to 18S rRNA content. Final results are expressed as n-fold differences of gene expression relative to calibrator. Data represent the mean +SD of values from at least three separate RNA samples (*p< 0.05, *** p< 0.001 versus calibrator). (H, K, N) Survival time in ACC patients according to the expression of SREBP1 (H), INSIG1 (K) and ABCG1 (N) genes. Statistical significance was calculated using t- test (A, B, C, H, K, N) or one-way analysis of variance followed by a Tukey post-hoc multiple comparison test (D, F, G, I, J, L, M), P<0.05 was considered significant.
FIGURE 2. Simvastatin reduces H295R cell growth, in vitro and in vivo. A. H295R cells were left untreated (0) or treated with increasing doses (2.5, 5, 10 uM) of simvastatin for 24 and 48 h. B) H295R cells were left untreated (0) or treated with increasing doses (2.5; 5; 10 uM) of simvastatin with or without mevalonate (200 µM) for 48h. A and B) Cell viability was evaluated by MTT assay (*p< 0.05, *** p<0.001 vs 0). C) Representative image of colony formation assay performed on H295R cells (1000 cells/well) plated for 2 weeks in the presence of simvastatin (2.5, 5, 10 µM). D) H295R cells were plated on low-attachment plates and then left untreated (0) or treated with Simvastatin (2,5, 5 and 10 uM), tumor-spheres formation efficiency (TSFE) was evaluated 5 days later (*p<0.05 vs untreated cells). E) H295R cells were injected subcutaneously in the flank region of nude mice and the resulting tumors were grown to an average of 200 mm3 21 days after inoculation and then treated with vehicle (n= 8) or simvastatin (n= 7) (4mg/kg/day) for 24 days. Values represent the mean ±SE of measured tumor volume over time (*p<0.05 versus control). F) Representative tumors and final tumor weights, values are mean ±SEM, (*p<0.05 vs vehicle). G) Ki67 immunohistochemistry and H&E staining of H295R xenografts (Magnification X 20, scale bar =25 um). Statistical significance was calculated using t-test (F) or one-way analysis of variance followed by a Tukey post-hoc multiple comparison test (A, B, D, E), P < 0.05 was considered significant
FIGURE 3. Simvastatin decreases cholesterol and aromatase content in ACC. A) H295R cells were left untreated (0) or treated for 48h with simvastatin (2.5, 5, 10 uM) in growth medium containing 10% lipoprotein-free serum. Cholesterol was extracted and measured by colorimetric
24
649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693
assay (*p< 0.05 vs untreated cells). B, bar graph) Cholesterol content in H295R xenografts samples (*p< 0.05 vs vehicle) (n=8 vehicle; n=7 Simvastatin). B, photograph) Frozen sections of H295R xenografts from vehicle- or simvastatin-treated mice were used for lipids droplets staining by Oil Red O (Magnification X40, scale bar 12,5um). C) H295R cells were treated for 48h with the indicated doses of simvastatin added to 5% DCC-FBS and estradiol (E2) release in the culture medium was measured by ELISA. Values represent the mean ±SE (*p< 0.05 vs untreated cells). D- F) H295R cells untreated (0) or treated for 24h with simvastatin (2.5, 5, 10 uM) were analyzed for CYP19 gene expression normalized to 18S rRNA by real-time PCR (D), and for SF-1 (E) or Aromatase (Arom) (F) protein content by WB. GAPDH was used as a loading control. Blots are from 1 representative experiment out of at least 3 performed. G) CYP19 expression in H295R xenografts samples from vehicle- or simvastatin-treated mice by real-time PCR (n=8 vehicle; n=7 Simvastatin). H) Immunohistochemical staining of Aromatase in untreated or simvastatin-treated H295R xenograft samples (Magnification X 20, scale bar =25 uM). Statistical significance was calculated using t-test (B, G) or one-way analysis of variance followed by a Tukey post-hoc multiple comparison test (A, C, D). P < 0.05 was considered significant.
FIGURE 4. Simvastatin reduces nuclear and mitochondrial ERa activity. A and C) WB analysis of ERa (A) and Cyclin E (C) was performed on equal amounts of total protein extracts from H295R cells left untreated (0) or treated with Simvastatin (2,5, 5 and 10 µM) for 48h. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. B and D) Immunofluorescence analysis of ERa expression (B) and immunohistochemical staining of Cyclin E (D) on H295R xenograft tumor samples obtained from vehicle- or simvastatin-treated mice (Magnification X 20, scale bar=25 uM). E and F) H295R cells untreated (0) or treated with simvastatin (5 uM) were used for mitochondrial protein extraction. ERa (E) and OXPHOS (F) protein expression was analyzed by WB. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. G and H) Immunostaining (G) and activity (H) of COX IV was evaluated on H295R xenograft samples obtained from vehicle- or simvastatin-treated mice (Magnification X 20, scale bar = 25um).
FIGURE 5. Simvastatin reduces mitochondrial functions. A-F) Mitochondrial respiration described as OCR (oxygen consumption rate) levels was detected in H295R cells left untreated or treated with Simvastatin (2.5, 5, 10 uM) for 16h by Seahorse XFe96 analyzer. A) The linear graph shows time course measurements but with three different injections to evaluate the OCR 1- after the oligomycin injection, 2- after the injection of carbonyl cyanide-(trifuoromethoxy)phenylhydrazone (FCCP), 3- after the injection of rotenone/antimycin. B-F) The histograms are derived from the obtained measurements: (B) basal respiration, (C) maximal respiration, (D) proton leak, (E) ATP turnover and (F) spare capacity (*p<0.05, *** p< 0.001 simvastatin vs untreated cells). G) Mitochondrial extracts from H295R cells treated for 48h were analyzed for TOM20 protein expression by WB. H) TOM20 protein expression was evaluated by immunohistochemistry on H295R xenograft samples obtained from vehicle- or simvastatin-treated mice (Magnification X 20, scale bar = 25um).
FIGURE 6. In vitro and in vivo activation of apoptosis by simvastatin in ACC. A) Cells were left untreated (0) or treated with simvastatin (2.5, 5, 10 uM) for 48h. WB analyses of Bak and PARP-1 were performed on equal amounts of total protein extracts. GAPDH was used as a loading
25
694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738
control. Blots are representative of three independent experiments with similar results. B) TUNEL assay was performed on cells treated as described in A). DAPI was used as nuclear counterstain. Fluorescent signal was observed under a fluorescent microscope. Images are from a representative experiment. C). TUNEL staining was performed on frozen sections of H295R xenograft samples obtained from vehicle- or simvastatin-treated mice (scale bar 25 um). D) WB analyses for p-cJun, c-Jun, pERK 1/2, ERK2, PARP-1, were performed on total protein extracted from cells treated for 48h with simvastatin (5 uM), mevalonate (100 uM), or their combination. E) WB analyses for p- cJun, Jun, pERK1/2, ERK2, PARP-1, were performed on total protein extracted from cells treated for 48 h with simvastatin (5 uM) alone or combined with PD98059 (10 uM), SP600125 (10 µM), SB203580 (10 µM). GAPDH was used as a loading control.
739 740 741 742 743 744 745 746 747 748
D
2
B
C
basal
14
A
HMGCR, 202540_s_at
HMGCR
HMGCR
1.0
intratumor cholesterol content (ng/g tissue)
GAPDH
N
0.8
40-
50-
*
HMG-CoA activity (Units/mgP)
40-
30
=
0.6
Prob.
low
30-
high
20-
0.4
20
0
10-
0.2
10-
0
- mit
+ mit
a>
high n=40
0.0
0
log-rank p= 0.7255
low n=38
basal
2 days
14 days
ACA
ACC
NC
0
50
100
150
Survival time (months)
E
single-organism metabolic process
single-organism biosynthetic process
oxoacid metabolic process
carboxylic acid metabolic process
organic acid metabolic process
organonitrogen com pound metabolic process
sm all molecule biosynthetic process
modulation of synaptic transmission
steroid metabolic process
single-organism process
intrinsic component of plasma membrane
ligase activity, forming carbon-oxygen bonds
ligase activity, form ing am inoacyl-tR NA and related com pounds
am inoacyl-tR NA ligase activity
cellular am ino acid metabolic process
cholesterol metabolic process
diacylglycerol metabolic process
intrinsic apoptotic signaling brown fat cell differentiation
0
5
10
15
20
Top 20 GO categories Enrichment score (basal vs mitotane)
F
1.5-
SREBF mRNA/18S rRNA (folg over basal)
0-
1.0-
0.5-
*
0.2
0.0
0
10
25
40
0
2w
3w
0
50
100
150
Mitotane [[M]
Mitotane
Survival time (months)
I
J
K
1.0
0.8
low
0.6
Prob.
0
high
0.2
0.0
0
10
25
40
0
2w
3w
Mitotane
0
50
100
150
Mitotane [uM]
H
1.0
0.8
high
0.6
Prob.
low
0.4
5
SREBF mRNA/18S rRNA (fold over basal)
1.5-
INSIG mRNA/18S rRNA (fold over basal)
1.0.
0.5-
**
INSIG mRNA/18S rRNA (fold over basal)
1.0-
0.5-
0.0
high n=24
0.0
log-rank p= 0.0051
low n=54
Survival time (months)
L
ABCG1 mRNA/18S rRNA (fold over basal)
1.5-
1.0-
0.5-
0.0
0
10
25
40
Mitotane [[M]
M
N
ABCG1
1.0
ABCG1 mRNA/18S rRNA (fold over basal)
2.0-
0.8
1.5-
0.6
low
1.0-
Prob.
0.4
high
0.5-
0.0
0.2
0
2w
3w
Mitotane
C
high n=39 low n=39
log-rank p= 0.7661
0
50
100
150
small molecule metabolic process
basal
mitotane
SREBF1
IDI1
INSIG1
FDXR
ABCG1
MVK
CEBPA
TM7SF2
OSBPL5
2.50
0.00
2.50
SREBF1
G
1.5-
0.0
0.0
log-rank p= 0.2274
high n=39 low n=39
INSIG1
1.5-
A
B
24h
48h
150
150
150-
mevalonate
125-
Cell viability (% of basal)
100
ns
100
Cell viability (% of basal)
100-
75-
50
50
50-
25-
0
0
0
5
10
0
2.5
5
10
0
2.5
0
2.5
5
10
Simvastatin [uM]
Simvastatin [uM]
Simvastatin [uM]
C
0
2.5
5
10
E
1600
1400
1.5
1200
vehicle
D
TSFE (Fold Change)
Tumor volume (mm3)
1000
1.0
800
*
600
- simvastatin
*
400
-
*
*
*
0.5
*
200
*
*
0
0
3
7
10
14
17
21
24
0.0
days of treatment
0
2.5
5
10
Simvastatin [uM]
F
G
vehicle
simvastatin
Ki67
1
2
3
4
5
8
EABLES
1
2
Tumor weight (g)
1.5
1.0
*
H&E
0.5
0.0
vehicle
simvastatin
B
intratumor cholesterol content (ng/g tissue)
A
12-
10
8.
25
*
Intracellular cholesterol (ng/mg protein)
6.
20
4-
15.
2-
*
0
vehicle
simvastatin
10
5
Oil-red-O
0
0
2.5
5
10
Simvastatin [uM]
C
D
Cellular E2 production (ng/ml/mg protein)
150
CYP19 mRNA/18S rRNA (fold/basal)
2.0-
100
1.5-
*
*
50
1.0-
0.5-
0
0
2.5
5
10
Simvastatin [uM]
0.0
0
2.5
5
10
[simvastatin] (u.M)
E
F
0
2.5
5
10
Simvastatin [uM]
0
2.5
5
10
Simvastatin [uM] Arom
SF-1
GAPDH
GAPDH
G
CYP19 mRNA/18S rRNA (% of vehicle)
150
H
vehicle
simvastatin
100
50-
Arom
0
vehicle
simvastatin
A
0
2.5
5
10
Simvastatin [M]
66KDa
ERa
46KDa
GAPDH
C
0 2.5 5 10 Simvastatin [M]
CCNE
GAPDH
E
0
5
66KDa
46KDa
ERa
36KDa
GAPDH
B
vehicle
simvastatin
ERa
D
vehicle
simvastatin
CCNE
F
0
5
ATP V
COX III
- COX II
- COX IV
COX I
H
COX IV
GAPDH
G
H
vehicle
simvastatin
vehicle
simvastatin
COX IV
COX IV activity
-
A
control
Fig. 5
600-
2.5 μ.Μ
5 µM
B
10 μΜ
200
OCR (pmol/min)
400-
Spare Capacity
Basal Respiration
150
100
200-
ATP Production
50
Basal Respiration
Maximal Respiration
0
Proton Leak
0
2.5
5
10
Non-mitochondrial Respiration
0
Simvastatin [[M]
0
15
35
48
66
Time (min)
C
D
400
40
ns
Maximal Respiration
ns
*
300
Proton Leak
30
200
20
100
10
0
0
2.5
5
10
0
0
2.5
5
10
Simvastatin [[M]
Simvastatin [[M]
E
F
150
300
Atp Turnover
Spare Capacity
100
200
50
100
0
0
0
2.5
5
10
0
2.5
5
10
Simvastatin [[M]
Simvastatin [[M]
H
vehicle
simvastatin
0 2.5 5 10
simvastatin [uM]
TOM20
TOM20
GAPDH
Downloaded from mct.aacrjournals.org on June 17, 2020. @ 2020 American Association for Cancer Research.
G
A
0 2.5 5 10
simvastatin [uM]
Bak
PARP
GAPDH
B
DAPI
TUNEL
MERGE
D
simvastatin
+
+
-
-
0
mevalonate
+
+
-
-
p-cJun
2.5
cJun
PERK1/2
5
ERK2
PARP-1
10
GAPDH
E
Simvastatin
+
+
+
+
-
-
-
PD
+
+
-
-
-
-
-
SP
+
+
-
-
-
-
-
C
SB
+
+
-
-
-
-
-
vehicle
p-cJun
cJun
simvastatin
PERK1/2
ERK2
Scale bars: 25um
PARP-1
GAPDH
AAGR American Association for Cancer Research
Molecular Cancer Therapeutics
Statins reduce intratumor cholesterol affecting adrenocortical cancer growth Francesca Trotta, Paola Avena, Adele Chimento, et al. Mol Cancer Ther Published OnlineFirst June 16, 2020.
| Updated version | Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-19-1063 |
| Supplementary Material | Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2020/06/16/1535-7163.MCT-19-1063.DC1 |
| Author Manuscript | Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. |
| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/early/2020/06/16/1535-7163.MCT-19-1063. Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) |